AVD 1173

Drug Profile

AVD 1173

Latest Information Update: 25 Feb 2005

Price : $50

At a glance

  • Originator Imaxio
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Growth disorders

Most Recent Events

  • 25 Feb 2005 Discontinued - Preclinical for Growth disorders in France (unspecified route)
  • 14 Jul 2003 Preclinical trials in Growth disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top